Alzheimer's Disease Clinical Trial
Official title:
Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology
Verified date | January 2, 2015 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- The Baltimore Longitudinal Study of Aging (BLSA) is a long-term study of human aging. To
see how the brain changes with age, researchers will study BLSA participants who are at least
60 years old. In particular, researchers are looking for early markers of possible
Alzheimer's disease and other conditions that cause memory loss. To do so, they will give
tests of memory and brain function, and stay in close contact with participants.
Objectives:
- To study cognitive changes that occur in normal aging and in people who develop memory
problems.
Eligibility:
- Individuals at least 60 years of age who are participating in the BLSA.
Design:
- There are three parts to this study. These study procedures will be done under the usual
BLSA guidelines.
- Participants will take paper and pencil tests. The tests measure skills such as
language, attention, memory, and problem solving. They will also ask questions about
emotions and feelings.
- Participants will give the name and phone number of a person who knows them well and
sees them often. Researchers will ask this person to fill out questionnaires on the
effects of aging on the participant. These questions will monitor the participant's
memory and ability to function independently.
- Participants will have regular phone calls between study visits. These calls will help
to keep their information up to date.
- Participants will continue on this study for as long as they are able to participate.
Status | Completed |
Enrollment | 2850 |
Est. completion date | January 2, 2015 |
Est. primary completion date | June 16, 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility |
- INCLUSION CRITERIA: All BLSA participants 60 years of age and older are included and will receive cognitive evaluations on their BLSA visits. EXCLUSION CRITERIA: Participants who are younger than 60 years old are excluded. Specialized testing procedures are adopted in the case of hearing or visual impairments |
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Aging, Clinical Research Unit | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute on Aging (NIA) | Johns Hopkins University |
United States,
Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int. 1984 Dec;26(6):861-8. — View Citation
Troncoso JC, Martin LJ, Dal Forno G, Kawas CH. Neuropathology in controls and demented subjects from the Baltimore Longitudinal Study of Aging. Neurobiol Aging. 1996 May-Jun;17(3):365-71. — View Citation
Zonderman AB, Giambra LM, Arenberg D, Resnick SM, Costa PT Jr, Kawas CH. Changes in immediate visual memory predict cognitive impairment. Arch Clin Neuropsychol. 1995 Mar;10(2):111-23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identifying early makers of cognitive and Alzheimer s disease | Ongoing | ||
Primary | Characterizing risk factors which modify progression to these states | Ongoing | ||
Primary | Cognitive changes associated with other health factors | Ongoing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT01920672 -
Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD
|
N/A |